BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27163741)

  • 1. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
    Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
    J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
    Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
    J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
    Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
    J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma.
    Krishnamurthy J; Rabinovich BA; Mi T; Switzer KC; Olivares S; Maiti SN; Plummer JB; Singh H; Kumaresan PR; Huls HM; Wang-Johanning F; Cooper LJ
    Clin Cancer Res; 2015 Jul; 21(14):3241-51. PubMed ID: 25829402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
    Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
    Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oxygen sensitive self-decision making engineered CAR T-cell.
    Juillerat A; Marechal A; Filhol JM; Valogne Y; Valton J; Duclert A; Duchateau P; Poirot L
    Sci Rep; 2017 Jan; 7():39833. PubMed ID: 28106050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
    Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.